Mapping and predicting mortality from systemic sclerosisMuriel Elhaï, Carlos Alberto von Mühlen, Serena Vettori et al.|Annals of the Rheumatic Diseases|2017Cited by 699
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) groupSuzana Jordan, Thierry Zénone, Jörg H. W. Distler et al.|Annals of the Rheumatic Diseases|2014Cited by 432
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohortCarina Mihai, Dorota Krasowska, Oliver Distler et al.|Lara D. Veeken|2019Cited by 29
Does the Impact of <scp>COVID</scp>‐19 on Patients With Systemic Sclerosis Change Over Time?Elisabeth Deibel, Fabian A. Mendoza, Patrícia Carreira et al.|Arthritis Care & Research|2023Cited by 2